673 related articles for article (PubMed ID: 26864033)
1. A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.
Lee YN; Lee YT; Kim MC; Gewirtz AT; Kang SM
J Immunol; 2016 Mar; 196(6):2637-45. PubMed ID: 26864033
[TBL] [Abstract][Full Text] [Related]
2. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.
Lee YN; Lee YT; Kim MC; Hwang HS; Lee JS; Kim KH; Kang SM
Immunology; 2014 Oct; 143(2):300-9. PubMed ID: 24773389
[TBL] [Abstract][Full Text] [Related]
3. CCR2 Regulates Vaccine-Induced Mucosal T-Cell Memory to Influenza A Virus.
Lee W; Kingstad-Bakke B; Kedl RM; Kawaoka Y; Suresh M
J Virol; 2021 Jul; 95(15):e0053021. PubMed ID: 33952647
[TBL] [Abstract][Full Text] [Related]
4. Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.
Hemann EA; Kang SM; Legge KL
J Immunol; 2013 Sep; 191(5):2486-94. PubMed ID: 23885108
[TBL] [Abstract][Full Text] [Related]
5. Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
Lee YN; Kim MC; Lee YT; Kim YJ; Lee J; Kim C; Ha SH; Kang SM
Antiviral Res; 2015 Oct; 122():82-90. PubMed ID: 26248203
[TBL] [Abstract][Full Text] [Related]
6. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.
Kim MC; Lee YN; Hwang HS; Lee YT; Ko EJ; Jung YJ; Cho MK; Kim YJ; Lee JS; Ha SH; Kang SM
Vaccine; 2014 Oct; 32(44):5824-31. PubMed ID: 25171841
[TBL] [Abstract][Full Text] [Related]
7. Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
PLoS One; 2018; 13(1):e0190868. PubMed ID: 29324805
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles.
Lee YT; Kim KH; Ko EJ; Kim MC; Lee YN; Hwang HS; Lee Y; Jung YJ; Kim YJ; Santos J; Perez DR; Kang SM
Virology; 2019 Mar; 529():111-121. PubMed ID: 30685658
[TBL] [Abstract][Full Text] [Related]
9. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
[TBL] [Abstract][Full Text] [Related]
10. Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets.
Music N; Reber AJ; Kim MC; York IA; Kang SM
Vaccine; 2016 Jan; 34(4):466-473. PubMed ID: 26709639
[TBL] [Abstract][Full Text] [Related]
11. Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.
Kim YJ; Lee YT; Kim MC; Lee YN; Kim KH; Ko EJ; Song JM; Kang SM
Front Immunol; 2017; 8():1730. PubMed ID: 29276514
[TBL] [Abstract][Full Text] [Related]
12. Conserved T-cell epitopes of respiratory syncytial virus (RSV) delivered by recombinant live attenuated influenza vaccine viruses efficiently induce RSV-specific lung-localized memory T cells and augment influenza-specific resident memory T-cell responses.
Matyushenko V; Kotomina T; Kudryavtsev I; Mezhenskaya D; Prokopenko P; Matushkina A; Sivak K; Muzhikyan A; Rudenko L; Isakova-Sivak I
Antiviral Res; 2020 Oct; 182():104864. PubMed ID: 32585323
[TBL] [Abstract][Full Text] [Related]
13. Influenza-induced lung T
Van Braeckel-Budimir N; Harty JT
Immunol Cell Biol; 2017 Sep; 95(8):651-655. PubMed ID: 28405016
[TBL] [Abstract][Full Text] [Related]
14. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
Wu F; Yuan XY; Huang WS; Chen YH
Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
[TBL] [Abstract][Full Text] [Related]
16. A Role of Influenza Virus Exposure History in Determining Pandemic Susceptibility and CD8+ T Cell Responses.
Quiñones-Parra SM; Clemens EB; Wang Z; Croom HA; Kedzierski L; McVernon J; Vijaykrishna D; Kedzierska K
J Virol; 2016 Aug; 90(15):6936-6947. PubMed ID: 27226365
[TBL] [Abstract][Full Text] [Related]
17. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
[TBL] [Abstract][Full Text] [Related]
18. Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
Altenburg AF; van de Sandt CE; van Trierum SE; De Gruyter HLM; van Run PRWA; Fouchier RAM; Roose K; Saelens X; Volz A; Sutter G; de Vries RD; Rimmelzwaan GF
J Virol; 2016 Nov; 90(22):10209-10219. PubMed ID: 27581985
[TBL] [Abstract][Full Text] [Related]
19. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.
Kim MC; Lee JS; Kwon YM; O E; Lee YJ; Choi JG; Wang BZ; Compans RW; Kang SM
Antiviral Res; 2013 Sep; 99(3):328-35. PubMed ID: 23811283
[TBL] [Abstract][Full Text] [Related]
20. Virus-specific T cells as correlate of (cross-)protective immunity against influenza.
Altenburg AF; Rimmelzwaan GF; de Vries RD
Vaccine; 2015 Jan; 33(4):500-6. PubMed ID: 25498210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
